Skip to main content
Clinical Trials/NCT02155868
NCT02155868
Completed
Not Applicable

Cerebral Near-Infrared Spectroscopy Monitoring in High-Risk Cardiac Surgery Patients: A Prospective, Randomised, Single-Blinded Study

Meshalkin Research Institute of Pathology of Circulation1 site in 1 country120 target enrollmentJune 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postoperative Complications
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Enrollment
120
Locations
1
Primary Endpoint
Incidence of postoperative complications
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Cerebral oximetry employing near-infrared spectroscopy (NIRS) is a non-invasive modality used to estimate regional cerebral oxygen content saturation (rSO2). Near-infrared spectroscopy has increasingly been used in perioperative setting of heart surgery and many studies have outlined an increased incidence of postoperative morbidity in patients with significant perioperative reductions in rSO2. Although a relationship between rSO2 reductions and adverse outcomes has been reported, there is not compelling evidence that interventions to correct rSO2 during cardiac surgery lead to improved clinical outcomes.

Hypothesis of the study is that interventions to normalize intraoperatively decreased cerebral rSO2 would reduce the overall incidence of postoperative complications in high-risk cardiac surgery patients.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
December 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible Party
Principal Investigator
Principal Investigator

Evgeny Fominskiy, MD, PhD

Mr

Meshalkin Research Institute of Pathology of Circulation

Eligibility Criteria

Inclusion Criteria

  • High-risk cardiac surgery patients as determined by at least one of the followings:
  • the age greater than or equal to 75 years on the day of screening;
  • left ventricle ejection fraction less than 35%;
  • use of a preoperative intraaortic balloon pump;
  • combined valve and coronary artery surgery or multiple valve surgery in patients who have congestive heart failure, or renal insufficiency (creatinine clearance \< 60 ml/min)

Exclusion Criteria

  • refusal of consent

Outcomes

Primary Outcomes

Incidence of postoperative complications

Time Frame: Up to 30 day after randomisation

This composite outcome includes: myocardial infarction, stroke, delirium, postoperative cognitive dysfunction, wound infection, mediastinitis, mechanical ventilation more than 24 h, arrhythmia, reoperation for bleeding, acute kidney injury, and acute kidney injury requiring dialysis.

Secondary Outcomes

  • Duration of postoperative hospital stay(Up to 30 day after randomization)
  • Incidence of major organ morbidity and mortality(Up to 30 day after randomization)
  • Death from all causes at 30 days(Up to 30 day after randomisation)
  • Duration of intensive care unit stay(Up to 30 day after randomization)

Study Sites (1)

Loading locations...

Similar Trials